Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Brentuximab vedotin in refract...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients

Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients

Bibliographic Details
Main Authors: Mathilde Lamarque, Céline Bossard, Adrien Contejean, Pauline Brice, Marie Parrens, Steven Le Gouill, Josette Brière, Reda Bouabdallah, Danielle Canioni, Hervé Tilly, Brigitte Bouchindhomme, Emmanuel Bachy, Richard Delarue, Corinne Haioun, Philippe Gaulard
Format: Article
Language:English
Published: Ferrata Storti Foundation 2016-03-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/7658
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://haematologica.org/article/view/7658

Similar Items

  • Brentuximab vedotin induced uveitis
    by: Stijn Therssen, M.D., et al.
    Published: (2022-06-01)
  • Brentuximab vedotin in pediatric Hodgkin lymphoma
    by: Shuvadeep Ganguly, et al.
    Published: (2022-01-01)
  • Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
    by: Hung-Bo Wu, et al.
    Published: (2013-01-01)
  • Overall survival with brentuximab vedotin in advanced Hodgkin lymphoma
    by: Shuvadeep Ganguly, et al.
    Published: (2022-01-01)
  • Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
    by: Chen R, et al.
    Published: (2015-03-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs